89Zr-trastuzumab

DIAGNOSTIC_TEST4 trials

Sponsors

Jules Bordet Institute, Memorial Sloan Kettering Cancer Center, Washington University School of Medicine, Centre de recherche du Centre hospitalier universitaire de Sherbrooke

Conditions

Breast Cancer MetastasesBreast Cancer MetastaticHER-2 Positive Breast CancerHER-2 Positive CancerHER2 Positive BreastHER2-positive Solid Tumor

Phase 1

HER2-PET Imaging in HER2-low Breast Cancers

RecruitingNCT06732336

Centre de recherche du Centre hospitalier universitaire de SherbrookeBreast Cancer Metastatic

Start: 2024-12-01End: 2027-03-31Target: 40Updated: 2026-03-31

Phase 2

HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1

CompletedNCT01565200

Jules Bordet InstituteHER-2 Positive Breast Cancer

Start: 2012-05-31End: 2022-12-31Updated: 2025-03-31

89Zr-Trastuzumab PET/CT in Subjects With Previously Treated HER2-Positive Solid Tumors Scheduled to Receive Treatment With MT-5111

WithdrawnNCT04757090

Washington University School of MedicineHER-2 Positive Cancer, HER2-positive Solid Tumor

Start: 2021-12-31End: 2023-12-31Updated: 2021-12-23

Unknown Phase

Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?

CompletedNCT02286843

Memorial Sloan Kettering Cancer CenterBreast Cancer Metastases, HER2 Positive Breast

Start: 2014-11-06End: 2020-06-30Updated: 2021-06-18

Related Papers

Detection of HER2-Low Lesions Using HER2-Targeted PET Imaging in Patients with Metastatic Breast Cancer: A Paired HER2 PET and Tumor Biopsy Analysis

Journal of Nuclear Medicine2025-05-085 citations

Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted <sup>89</sup>Zr-Pertuzumab PET/CT

Radiology2020-06-0968 citations

89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.

2017-12-0190 citations

Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.

2015-11-23264 citations

PET/CT with 89Zr-trastuzumab and 18F-FDG to individualize treatment with trastuzumab emtansine (T-DM1) in metastatic HER2-positive breast cancer (mBC).

Journal of Clinical Oncology2014-05-2018 citations